Announcements
- Monopar Announces CFO Succession
- Monopar Therapeutics Reports First Quarter 2024 Financial Results and Strategic Focus on its Radiopharma Pipeline
- Monopar Announces Radiopharma Presentation Selected for Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting
- Monopar Announces Filing of Patent Protecting MNPR-101 Radiopharma Optimization Findings
- Monopar Initiates Radiopharma Phase 1 Clinical Trial for MNPR-101-Zr in Advanced Cancer Patients
- Monopar Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Developments
- Monopar Announces Positive Preclinical Therapeutic Isotope Data for its MNPR-101 Radiopharma Program
- Monopar Provides Update on MNPR-101-Zr Radiopharma Clinical Trial
- Monopar Announces Promising Preclinical Data for its MNPR-101 Radiopharma Program Targeting Advanced Cancers
- Monopar Receives Clearance to Proceed with First-in-Human Phase 1 Trial of Novel Radiopharmaceutical MNPR-101-Zr in Advanced Cancers
More ▼
Key statistics
As of last trade, Monopar Therapeutics Inc (1IY:MUN) traded at 0.57, 111.11% above the 52 week low of 0.270 set on Nov 22, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.57 |
---|---|
High | 0.57 |
Low | 0.57 |
Bid | 0.555 |
Offer | 0.575 |
Previous close | 0.57 |
Average volume | 0.00 |
---|---|
Shares outstanding | 17.48m |
Free float | 8.35m |
P/E (TTM) | -- |
Market cap | 10.84m USD |
EPS (TTM) | -0.5289 USD |
Data delayed at least 15 minutes, as of May 29 2024 07:04 BST.
More ▼